The Cancer Advances podcast is joined by Wen Wee Ma, MBBS, Director of the Novel Cancer Therapeutics Center, and Lucy Boyce Kennedy, MD, Director of the Oncology Pharmacovigilance Clinic. Listen as they discuss how this new Oncology Pharmacovigilance Clinic enhances patient care by addressing complex toxicities and side effects from immunotherapy treatment, and integrates specialists from rheumatology, endocrinology, pulmonology and more.

Nima Almassi, MD, a Urologic Oncologist at Cleveland Clinic, joins the Cancer Advances Podcast to discuss managing non-muscle-invasive bladder cancer with variant histologies. Listen as Dr. Almassi talks about effectiveness of intravesical therapy, the importance of specialized pathology reviews, and the potential need for early cystectomy in aggressive variants.

Roberto Vargas, MD, gynecologic oncologist at Cleveland Clinic, joins the Cancer Advances Podcast to discuss adding immunotherapy to chemotherapy for endometrial cancer. Listen as Dr. Vargas sheds light on recent studies demonstrating that adding checkpoint inhibitors to standard chemotherapy could notably lower the risk of cancer recurrence in patients with MMR-deficient or MSI-high tumors and the potential of genomic-based therapies for endometrial cancers.

Erin Murphy, MD, Director of Pediatric Radiation Oncology at Cleveland Clinic, joins the Cancer Advances Podcast to discuss stereotactic radio surgery (SRS) for adolescent and young adult brain and spine tumors. Listen as Dr. Murphy highlights the benefits of SRS for younger patients, including shorter treatment intervals, less impact on daily routine and recovery, and the ability to continue with school during treatment.

The Cancer Advances podcast is joined by Ofer Reizes, PhD, the Laura J. Fogarty Endowed Chair for Uterine Cancer Research, and Justin Lathia, PhD, Melvin H. Burkhardt Endowed Chair for Neuro-Oncology Research, Scientific Director of the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, and the Vice Chair of the Department of Cardiovascular and Metabolic Sciences at Cleveland Clinic's Lerner Research Institute to discuss their research on peptide therapy as a targeted treatment for triple negative breast cancer. Listen as they explain their collaborative efforts to develop therapeutic peptides that disrupt cancer stem cell programs, the process of their work, and the potential for expanding peptide therapy to other cancer types.

Young-onset colorectal cancer is becoming more common, and the microbiome could be playing a role in the increase of cases. Alok Khorana, MD, Director of the Gastrointestinal Malignancies Program at Cleveland Clinic Cancer Institute, joins the Cancer Advances Podcast to discuss this issue. Listen as Dr. Khorana highlights his research on the link between changes in the microbiome and the development and progression of colorectal cancer in younger patients. He also discusses the ongoing metabolomic analysis and investigations.

The Cancer Advances podcast is joined by colorectal surgeons, I. Emre Gorgun, MD, Vice Chair of the Department of Colorectal Surgery, and Joshua Sommovilla, MD, Director of the Colon Cancer Tumor Board, to talk about organ preservation in rectal cancer treatment. Listen as they discuss the rising use of neoadjuvant therapy to shrink tumors before surgery, endoluminal procedures, and the importance of close surveillance and follow-ups for patients.

Shilpa Gupta, MD, Director of the Genitourinary Oncology Program at Cleveland Clinic Cancer Institute, provides an overview of the clinical trial of enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. Listen as Dr. Gupta talks about the exciting results of the trial, which showed that the combination therapy was effective for both cisplatin-eligible and cisplatin-ineligible patients. She also highlights the future studies that are being conducted to explore the use of the therapy in the neoadjuvant setting.